Oliver Schoor joined Immatics in 2005 and heads the Target Research Department dedicated to target discovery and validation.
Making use of the immune system to fight cancer has been the guiding theme of Oliver’s career. His initial role with Immatics focused on scientifically and technically strengthening Immatics’ proprietary XPRESIDENT® technology platform, which has been the source of true cancer targets for all of Immatics’ therapeutic approaches. Over time, Oliver held several different positions in project and alliance management for internal research programs as well as in the context of collaborations with the pharmaceutical industry and other external partners.
Oliver Schoor holds a Diploma in Biochemistry and a Ph.D. in Immunology from the University of Tübingen.